Oncotarget

Research Papers:

A comprehensive characterization of rare mitochondrial DNA variants in neuroblastoma

Francesco Maria Calabrese, Rosanna Clima, Piero Pignataro, Vito Alessandro Lasorsa, Michael D. Hogarty, Aurora Castellano, Massimo Conte, Gian Paolo Tonini, Achille Iolascon, Giuseppe Gasparre and Mario Capasso _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:49246-49258. https://doi.org/10.18632/oncotarget.10271

Metrics: PDF 1704 views  |   HTML 1861 views  |   ?  


Abstract

Francesco Maria Calabrese1,*, Rosanna Clima2,*, Piero Pignataro3,4, Vito Alessandro Lasorsa3,4, Michael D. Hogarty5, Aurora Castellano6, Massimo Conte7, Gian Paolo Tonini8, Achille Iolascon3,4, Giuseppe Gasparre2,#, Mario Capasso3,4,9,#

1Department of Biology, University of Bari “Aldo Moro”, Bari, Italy

2Department of Medical and Surgical Sciences-DIMEC, Medical Genetics Unit, University of Bologna, Bologna, Italy

3Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy

4CEINGE Biotecnologie Avanzate, Napoli, Italy

5Department of Pediatrics, Division of Oncology, Children’s Hospital of Philadelphia, Perelman School of Medicine at The University of Pennsylvania, Philadelphia, USA

6Paediatric Haematology/Oncology Department, IRCCS, Ospedale Pediatrico Bambino Gesù, Rome, Italy

7Oncology Unit, IRCCS Istituto Giannina Gaslini, Genova, Italy

8Pediatric Research Institute (IRP) – Fondazione Città della Speranza, Neuroblastoma Laboratory, Padua, Italy

9IRCCS SDN, Istituto di Ricerca Diagnostica e Nucleare, Naples, Italy

*These authors contributed equally to this work

#Co-last authors

Correspondence to:

Mario Capasso, email: mario.capasso@unina.it

Keywords: neuroblastoma, mitochondrial DNA mutations, WES, somatic mutations, germline mutations

Received: April 21, 2016     Accepted: June 09, 2016     Published: June 24, 2016

ABSTRACT

Background: Neuroblastoma, a tumor of the developing sympathetic nervous system, is a common childhood neoplasm that is often lethal. Mitochondrial DNA (mtDNA) mutations have been found in most tumors including neuroblastoma. We extracted mtDNA data from a cohort of neuroblastoma samples that had undergone Whole Exome Sequencing (WES) and also used snap-frozen samples in which mtDNA was entirely sequenced by Sanger technology. We next undertook the challenge of determining those mutations that are relevant to, or arisen during tumor development. The bioinformatics pipeline used to extract mitochondrial variants from matched tumor/blood samples was enriched by a set of filters inclusive of heteroplasmic fraction, nucleotide variability, and in silico prediction of pathogenicity.

Results: Our in silico multistep workflow applied both on WES and Sanger-sequenced neuroblastoma samples, allowed us to identify a limited burden of somatic and germline mitochondrial mutations with a potential pathogenic impact.

Conclusions: The few singleton germline and somatic mitochondrial mutations emerged, according to our in silico analysis, do not appear to impact on the development of neuroblastoma. Our findings are consistent with the hypothesis that most mitochondrial somatic mutations can be considered as ‘passengers’ and consequently have no discernible effect in this type of cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 10271